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Posttransplant Hypertension in Blacks Versus Nonblacks 
V. Scantlebury, J. McCauley, H. Woods, R. Shapiro, W. Irish, J. McMichael, M. Jordan, C. Vivas, J.J. Fung, 
and T.E. Starzl 
HYPERTENSION (HTN) is known to be a major 
cause of end-stage renal disease in the black popu-
lation. I •2 However. the onset ofHTN after renal transplan-
tation is also a common problem and has been shown to be 
associated with such factors as renal dysfunction. native 
renal disease. and drug toxicity.) We analyzed our renal 
transplant patient population looking at the required max-
imum number of antihypertensive medications (AHMs) in 
the postoperative period to see if there were any differ· 
ences between black (BK) and nonblack (NBK) renal 
transplant recipients. 
MATERIALS AND METHODS 
A retrospective review of all renal transplants followed at our 
institution between January 1987 and January 1992 was carried 
out. and all patients requiring AHMs with follow-up and graft 
function for at least I year were analyzed. Of 361 patients on 
AHMs, 230 were eligible for analysis. Median follow-up was 28 
months (range 12 to 72 months). Maintenance immunosuppressive 
regimens consisted of cyclosporine (eyA). prednisone ± azathio-
prine. and FK 506. prednisone ± azathioprine. Patients were 
categorized by race into BK and NBK. The mean maximum 
number of AHM required by the two groups of patients were 
examined and analyzed to see if race. sex. age. type of immuno-
suppression. or graft number played any role in the requirement of 
AHMs. 
RESULTS 
Of the 230 patients evaluated. 34 were BK (15%) and 196 
were NBK (85%). The mean maximum number of required 
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fig 1. Posttransplant hypertension in blacks vs nonblacks. 
AHM were similar for both groups: 2.2 ± 0.9 for BK and 
1.9 ± 1.0 for NBK (Table I). Males accounted for 64% of 
patients (147), while females made up 36% of patients (83). 
The major difference was seen when the numbers of 
AHMs required were compared between males and fe-
males: Male patients had a mean maximum number of 2.1 
± 0.8 compared with 1.7 ± 1.0 for females (P = .(03). This 
sex difference was also shown to be true within the BK and 
NBK grouPS. with a numerical difference but no statistical 
significance (Fig 1). Patients on cyclosporine-based immu· 
nosuppression had slightly higher mean maximum num· 
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bers of AHMs (2.1 :!: 0.8) when compared with patients on 
FK 506-based immunosuppression (1.9 :!: 1.0). but these 
differences were not statistically significant. Recipient age 
was examined and patients were categorized as pediatric 
(less than 18 years). greater than 50 years. or less than 50 
years of age. Patients were also categorized as undergoing 
either primary or retransplantation. When each of these 
variables were analyzed to see if race was a factor in the 
use of the mean maximum number of AHMs after renal 
transplantation. no significant correlation could be demon-
strated (Table I). 
DISCUSSION 
Black recipients were shown to require slightly but not 
significantly higher numbers of AHMs postoperatively. 
The only significant difference in this study was between 
males and females. When the two groups (BK and NBK) 
were examined by sex. age. type of immunosuppressive 
2457 
agent. or graft number. none of these factors contributed 
to the mean maximum number of AHMs required postop-
eratively. FK 506 has been reported to have a lower 
incidence of HTN when compared with CyA.4 but in this 
analysis no significant difference in the two drugs could be 
shown. Retransplantation also played no role in the re-
quirements for AHMs after renal transplantation. Our 
findings. therefore. do not indicate that hypertension after 
renal transplantation is worse in black than in nonblack 
recipients. 
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